GLP-1
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
Research is emerging showing a causal link between COVID-19 and diabetes. Dr. Brian Fertig, M.D., founder and president of the Diabetes & Osteoporosis Center in New Jersey, spoke with BioSpace.
ShouTi believes many targets addressed by biologic and peptide therapeutics can be reached by innovative, rationally-designed, best-in-class small molecules that don’t need refrigeration or injection.
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
With data siloed with various researchers and departments, it is broadly inaccessible and eventually forgotten. Digital management has become the new bottleneck in biotech development.
In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk’s semaglutide.
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
PRESS RELEASES